Cargando…
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer
Interstitial lung disease (ILD) occurrence and risk factors were investigated in the Japanese non-small-cell lung cancer, post-marketing, large-scale surveillance study, POLARSTAR. All patients with unresectable, recurrent/advanced non-small-cell lung cancer who were treated with erlotinib in Japan...
Autores principales: | Gemma, Akihiko, Kudoh, Shoji, Ando, Masahiko, Ohe, Yuichiro, Nakagawa, Kazuhiko, Johkoh, Takeshi, Yamazaki, Naoya, Arakawa, Hiroaki, Inoue, Yoshikazu, Ebina, Masahito, Kusumoto, Masahiko, Kuwano, Kazuyoshi, Sakai, Fumikazu, Taniguchi, Hiroyuki, Fukuda, Yuh, Seki, Akihiro, Ishii, Tadashi, Fukuoka, Masahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317960/ https://www.ncbi.nlm.nih.gov/pubmed/25287435 http://dx.doi.org/10.1111/cas.12550 |
Ejemplares similares
-
Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients
por: Yamazaki, Naoya, et al.
Publicado: (2015) -
Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis
por: Goto, Koichi, et al.
Publicado: (2016) -
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
por: Monteleone, Nicholas J., et al.
Publicado: (2020) -
The St. George’s Respiratory Questionnaire as a prognostic factor in IPF
por: Furukawa, Taiki, et al.
Publicado: (2017) -
Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non–small cell lung cancer
por: Saito, Yoshinobu, et al.
Publicado: (2021)